Anti hyperuricemic gout has a billion market in China! Still growing fast!

According to the "consensus of Chinese experts on hyperuricemia and gout treatment" released by the endocrinology branch of the Chinese Medical Association, at present, China's hyperuricemia (Hua) has a trend of high prevalence, younger age, higher male than female, higher coastal than inland Hyperuricemia is an independent risk factor of many cardiovascular risk factors and related diseases, which is the direct cause of gout none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the new compound product has been approved by FDA for listing in recent years In recent years, there are fewer drugs for hyperuricemia and gout treatment in the world, which is out of line with the high growth trend of gout Clinically, the anti gout drugs are allopurinol, which was listed in 1960s, and febuxostat, which was approved by Takeda and Ipsen in 2009 However, these drugs are not suitable for all gout patients, and new gout drugs are urgently needed in the market In December 2015, the US FDA approved the listing of lesinurad, a new hyperuricemia drug developed by Ardea Biosciences, a subsidiary of AstraZeneca, under the trade name of zurampuc Recilanide is a selective oral tablet of uric acid reuptake inhibitors Its mechanism is to help the kidney excrete uric acid and play a role by inhibiting the function of transporters involved in the reabsorption of uric acid in the kidney However, oral administration of racinade alone is not significant for gout Only with allopurinol can it be used for the treatment of gout patients with hyperuricemia Under the situation of limited business prospects of zurampuc, in April 2016, AstraZeneca and Ironwood pharmaceutical company reached an exclusive license agreement for the commercial rights of zurampuc in the U.S market In addition, its European interest was transferred by Gr ü nenthal On August 22, 2017, the US FDA approved Ironwood's first gout compound drug, lesinurad + allopurinol, under the trade name of duzallo This is the first fixed dose combination drug approved by FDA, which promotes the market of new anti gout drugs none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; The incidence rate of gout in China is 0.20%~0.35%, while the incidence rate of gout in men is 20 times that of women Gout is an arthritis disease caused by excessive uric acid, an end product of purine metabolism in serum In recent years, with the change of diet structure and the excessive intake of high purine food, the incidence of gout has shown an increasing trend It has become the third kind of rich disease after hyperglycemia and hyperlipidemia According to the statistics of Chinese drug application and surveillance, the incidence rate of hyperuricemia in China is 10%, about 130 million potential population, and about 17 million gout patients It has become the second largest metabolic disease in China, and has aroused extensive attention in this treatment market none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box sizing: border box! Im assistant; word wrap: break word! Im assistant; "> the four varieties have obvious advantages, with high concentration There are five varieties of anti gout drugs in 2017 medical insurance drug catalog, including non bustard, benbromarone, allopurinol, colchicine and probenecid According to the data of minenet, the market sales of targeted anti gout drugs in 2016 was 729 million yuan Among them, the drugs for hyperuricemia and gout treatment in public hospitals in key cities were 129 million yuan, an increase of 52.88% year-on-year, which was a high growth rate category The market was monopolized by four drugs, namely non bustard, benbromarone, allopurinol and colchicine Among them, 38.28% were non bustatin, 31.62% were benzbromarone, 16% were allopurinol and 14.10% were colchicine It is predicted that the sales volume of targeted anti gout drugs in the domestic market in 2017 will reach 1 billion yuan There are more manufacturers involved in anti gout drugs in China, including 25 public hospitals in key cities, with the top 5 manufacturers accounting for 86.68% of the total Jiangsu Wanbang is the first, accounting for 27.32%; excella is the second, accounting for 21.16%; Heilongjiang aolidaned is the third, accounting for 14.69%   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> febuxostat is a new drug for the treatment of hyperuricemic gout On February 13, 2009, Japan's febuxostat was approved by the U.S FDA for listing Its trade name is Uloric It is the first gout drug approved by the U.S FDA for the treatment of hyperuricemic gout in nearly 40 years In China, as a class B drug in the 2017 medical insurance catalog, it is used for patients with renal insufficiency and allopurinol allergic gout Non bustast is a new and efficient selective inhibitor of non purine xanthine oxidase It can reduce the level of uric acid in the blood of patients with hyperuricemia and gout without inhibiting other enzymes involved in the uric acid pathway, so it is safer than allopurinol In 2013, non bustard developed in China was listed on the market According to the data on CFDA's official website, Hangzhou zhuyangxin Pharmaceutical Co., Ltd., Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd and Jiangsu Hengrui Pharmaceutical Co., Ltd have been approved to list three non brescial preparations in China In 2016, the amount of non bustard drugs used in public hospitals in key cities in China was 57.19 million yuan, an increase of 153.28% over the previous year Youlitong, Jiangsu Wanbang Biochemical Medicine Co., Ltd., Ruiyang, Jiangsu Hengrui and fengdingning, Hangzhou zhuyangxin Pharmaceutical Co., Ltd accounted for 61.74%, 29.74% and 8.52% respectively Form the potential of domestic medicine     none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> benbromarone is the main product in the current domestic gout market CFDA released information on December 31, 2014, which indicated that liver damage was more prominent in the serious adverse reactions of benzbromarone The drug caused liver function abnormality and the rise of glutamic oxaloacetate, glutamic pyruvate transaminase and alkaline phosphatase, which cast a shadow on the market prospect of benzbromarone In 2000, benbromarone was listed on the market in China At present, the imported drug on the market is narcaricin mite, the benbromarone tablet of Sano arzneimittelfabrik GmbH of Germany Domestic benzbromarone oral preparations are produced by Changzhou CommScope Pharmaceutical Co., Ltd., Kunshan longdengruidi Pharmaceutical Co., Ltd., Chengdu Huashen Group Co., Ltd and Yichang East Sunshine Changjiang Pharmaceutical Co., Ltd In 2016, the amount of benbromarone used in public hospitals in key cities in China was 47.24 million yuan, an increase of 17.05% over the previous year Among them, imported drugs accounted for 57.90%; domestic drugs accounted for 42.10% Among them, bulixian of longdengruidi in Kunming accounts for 28.31%, ertongshu of Yichang East Sunshine Changjiang pharmaceutical industry accounts for 8.56%, Yunuo of Changzhou CommScope pharmaceutical industry accounts for 4.54%, and milong of Taihe health Huashen in Chengdu accounts for 0.68% none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0,0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> allopurinol is the first drug to treat chronic gout, and it is also the main drug to effectively reduce the production of uric acid and the level of blood uric acid in clinical treatment of primary gout Allopurinol is a drug approved by FDA for many years So far, 17 domestic enterprises have produced allopurinol oral tablets In 2016, the amount of allopurinol used in public hospitals in key cities in China was 23.93 million yuan, an increase of 14.28% over the previous year Top 5: Heilongjiang aolidaned accounted for 79.33%, world trade Tianjie for 8.94%, Shanghai Xinyi for 7.29%, Chongqing Qingyang for 3.83%, and Guangzhou Kanghe for 0.25% none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> colchicine ups and downs colchicine is an effective drug for the treatment of acute gout, which can effectively alleviate the pain of gout attack, especially for the treatment of acute gout arthritis, and play an anti-inflammatory treatment can effectively prevent the recurrence of gout However, 50% - 80% of the patients taking colchicine had gastrointestinal adverse reactions before the onset of gout was relieved, which affected the growth of colchicine market On the other hand, apart from the import of colchicine from India, only Kunming Pharmaceutical Group and Xishuangbanna pharmaceutical industry produced colchicine in China In 2016, the amount of colchicine used in public hospitals in key cities in China was 900000 yuan, an increase of 33.98% over the previous year Top 5: Kunming Pharmaceutical accounts for 49.01%, Yunnan Plant Pharmaceutical accounts for 21.47%, Xishuangbanna pharmaceutical accounts for 9.58%, Jingde Pharmaceutical (Taiwan) accounts for 7.21%, Guangdong bidi accounts for 5.56%, and other companies account for 7.17%.